FUJIFILM Cellular Dynamics, a developer and manufacturer of human induced pluripotent stem cells (iPSCs), has announced the global launch of its iCell Sensory Neurons.
These human iPSC-derived neurons are designed to support scientists in neuroscience research, drug discovery for novel pain medications, and neurotoxicity analysis.
FUJIFILM Cellular Dynamics will showcase the iCell Sensory Neurons and other key products from its neuroscience portfolio at the Society for Neuroscience annual conference in early October in Chicago, followed by the Annual Pain Therapeutics Summit in Boston in the same month.
The iCell Sensory Neurons are off-the-shelf, ready-to-use, human iPSC-derived cell models. They demonstrate the expression and function of key drug discovery targets for nociception through expression and function.
FUJIFILM Cellular Dynamics said that these neurons are ideal for research in the drug discovery sector.
In addition, they show functional responses to sensory agonists within 21 days of culture.
The iCell Sensory Neurons also feature low spontaneous activity and consistent lot-to-lot purity.
Fujifilm Cellular Dynamics, a biotechnology arm of Japan-based Fujifilm, offers support for large-scale iPSC-derived cell manufacturing.
The cells are derived from both male and female iPSC backgrounds. They are available as a kit with proprietary media for optimal maintenance or as a standalone product.
FUJIFILM Cellular Dynamics executive vice president Keith Olson said: “We are excited and proud to be showcasing this new product at multiple conferences this October to provide neuroscience researchers and cancer researchers with this biologically relevant model to study human disease and the targets involved in the sensation of pain.”
FUJIFILM Cellular Dynamics’ human iPSCs are crucial for drug discovery, contract development, and cell therapies.
The company applies its iPSC expertise to create cell therapeutics for conditions like age-related macular degeneration, retinitis pigmentosa, and heart diseases.
It supports its partners by advancing therapeutic candidates in clinical trials and providing contract development and manufacturing (CDMO) services.
In addition to cell therapy, the company offers life science research tools, including iCell products. These products cover a range of cell types and are sourced from various cell lines.
In December 2023, FUJIFILM announced an investment of $200m in FUJIFILM Cellular Dynamics and FUJIFILM Diosynth Biotechnologies for capacity expansion.
